Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials
Sean P David1, Elaine C Johnstone, Michael Churchman
1Center for Education and Research in Family and Community Medicine, 1215 Welch Road, Modular G, Stanford University School of Medicine, Stanford, CA 94305, USA. spdavid@stanford.edu
Introduction:
Cigarette smoking remains the leading cause of preventable death worldwide. However, the efficacy of available first-line therapies remains low, particularly in primary care practice where most smokers seek and receive treatment. These observations reinforce the notion that 'one size fits all' smoking cessation therapies may not be optimal. Therefore, a translational research effort was launched by the Imperial Cancer Research Fund (later Cancer Research UK) General Practice Research Group, who led a decade-long research enterprise that examined the influence of pharmacological hypothesis-driven research into genetic influences on drug response for smoking cessation with transdermal nicotine replacement therapy in general practice.
Methods:
New and previously published smoking cessation genetic association results of 30 candidate gene polymorphisms genotyped for participants in two transdermal nicotine replacement clinical trials based in UK general practices, which employed an intention to analyze approach.
Results:
By this high bar, one of the polymorphisms (COMT rs4680) was robust to correction for multiple comparisons. Moreover, future research directions are outlined; and lessons learned as well as best-practice models for designing, analyzing, and translating results into clinical practice are proposed.
Conclusions:
The results and lessons learned from this general practice-based pharmacogenetic research programme provide transportable insights at the transition to the second generation of pharmacogenetic and genomic investigations of smoking cessation and its translation to primary care.
Insights
Pharmacogenetic research identified the COMT rs4680 polymorphism as a key factor in smoking cessation success with nicotine replacement therapy. This finding advances personalized medicine in primary care for smokers.
Area of Science:
- Pharmacogenetics
- Genomics
- Translational Research
Background:
- Cigarette smoking is a leading cause of preventable death globally.
- Current first-line smoking cessation therapies have limited efficacy, especially in primary care.
- A personalized medicine approach is needed for effective smoking cessation.
Purpose of the Study:
- To investigate genetic influences on smoking cessation treatment response.
- To examine the efficacy of transdermal nicotine replacement therapy (TNRT) in general practice.
- To translate pharmacogenetic findings into clinical practice.
Main Methods:
- Analyzed genetic association results of 30 candidate gene polymorphisms.
- Utilized data from two TNRT clinical trials in UK general practices.
- Employed an intention-to-treat analysis approach.
Main Results:
- The COMT rs4680 polymorphism was robustly associated with smoking cessation success.
- This finding remained significant after correction for multiple comparisons.
- Future research directions and best-practice models were proposed.
Conclusions:
- Pharmacogenetic research in general practice offers valuable insights for smoking cessation.
- Findings support the transition to a second generation of genomic investigations.
- Personalized smoking cessation strategies can be translated into primary care settings.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
01:29Pharmacogenomics: Identification of New Drug Targets
01:27Pharmacogenetics of Drug Metabolism: Overview
01:27Principles of Pharmacogenetics: Types of Genetic Variants
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase